Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively. At the time of diagnosis and surgical resection of the primary tumour, most patients do not have clinical signs of metastases, but bone micrometastases may already be present. Our aim was to develop a novel preclinical ILC model of spontaneous bone micrometastasis. We used murine invasive lobular breast carcinoma cells (KEP) that were generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1( 
Introduction
Breast cancer is the most common malignancy among females in the Western world, affecting 12% of the female population. Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the most frequently occurring histological subtypes of breast cancer, accounting for 80-90% and 10-15% of the total cases, respectively [1, 2] . For both subtypes, bone is the preferred site of metastasis, leading to incurable and painful disease [3] .
Although at the time of diagnosis most breast cancer patients may not have clinical pathological signs of metastases, micrometastases are often present, representing a disease stage called 'minimal residual disease' (MRD). The micrometastases may stay dormant for many years before developing into clinically overt metastases. Hence, there is an urgent need for a preclinical in vivo model that mimics these key events during breast cancer progression. Such preclinical models will facilitate the development of a novel treatment for advanced breast cancer aiming at improving clinical outcome. Unfortunately, most of the currently available in vivo bone metastasis models do not reflect the complex, multistep process of metastasis [4, 5] . For example, models that rely on intra-arterial inoculation of cancer cells only represent later stages of metastasis, i.e. tumour cell extravasation, and homing to distant sites.
Genetically engineered mouse models (GEMMs) of de novo tumourigenesis and subsequent metastasis formation offer several advantages. Tumours derived from GEMMs often closely recapitulate the histopathological characteristics observed in clinical material. Moreover, tissue-specific induction of mutations gives rise to orthotopic tumours in the context of a functional, competent microenvironment, thus recapitulating the crosstalk between the tumour and its stroma. Unfortunately, GEMMs often yield a relatively low incidence of metastatic disease [6] . Direct inoculation of cancer cells into the mammary fat pad of mice generally results in tumour take in an anticipated time frame, while still carefully reflecting cancer cell intrinsic traits of the carcinomas.
Most orthotopic models of breast cancer, however, do not result in multiple, detectable metastases to bones. In the highly aggressive, E-cadherin-expressing 4 T1 triple-negative murine breast cancer model, small skeletal metastases only occur at late stage, while these mice have suffered from multiple, debilitating lung metastases and invasively growing orthotopic cancer cells [7] [8] [9] . In this study, we set out to develop a novel, clinically relevant mouse model of MRD for ILC by exploiting a cell line derived from the well-characterized conditional K14cre;Cdh1 F/F ;Trp53 F/F mouse model of de novo mammary tumour formation [10] .
Transforming growth factor-β (TGFβ) plays an essential role in maintaining physiological epithelial homeostasis in many tissues through its ability to induce cell cycle arrest, differentiation, and apoptosis, thereby preventing uncontrolled proliferation [11, 12] . However, in tumour progression, cancer cells often become refractory to this growth inhibition, and pro-tumourigenic actions of TGFβ may prevail, including immunosuppression, angiogenesis, and acquisition of an invasive phenotype [11, 12] . In many preclinical breast cancer models, pharmacological inhibition of TGFβ signalling was found to reduce metastasis to lung and bone in GEMMs and xenograft mouse models [13] [14] [15] [16] [17] . Therefore, many drugs that target the TGFβ pathway have been developed, some of which are currently being tested in clinical trials [13, 18] . However, the effects of blocking TGFβ signalling have not yet been studied in preclinical models of ILC.
Materials and methods

Cell line and culture conditions
The murine invasive lobular carcinoma cell line (KEP) was generated by targeted deletion of E-cadherin and p53 in a conditional K14cre;Cdh1( F/F );Trp53( F/F ) mouse model as described previously [10] . The lentivirally luciferase transduced clones KEP1_11/Luc (KEP11/Luc) and KEP1_23/Luc (KEP23/Luc) were cultured in DMEM-F12 supplemented with 10% FCS, 50 IU/ml penicillin, 50 ng/ml streptomycin, 5 ng/ml insulin, and 5 ng/ml EGF (Sigma-Aldrich, Zwijndrecht, The Netherlands). Cell lines were tested for Mycoplasma contamination by PCR prior to use.
Luciferase reporter gene constructs
The CAGA 12 reporter construct consists of 12 Smad3/ Smad4 binding sequences (CAGA boxes) [19] and was coupled to a Renilla luciferase to detect intracellular Smad3/4-dependent TGFβ signalling.
DNA staining for cell cycle analysis KEP cells were seeded (100 000 in T25) and stimulated the subsequent day with TGFβ1 (R&D Systems, Abingdon, UK) and/or SD-208 (Epichem Pty Ltd, Murdoch University, Australia), a small molecule that blocks ATP binding to the TGFβ receptor I (TβRI) to specifically inhibit its kinase activity [20] . Cells cultured for 72 h in serum-deprived media were used as positive controls for increase in G0/1. After 24 or 48 h of stimulation, cells were washed twice with PBS and harvested using 0.1% trypsin/EDTA solution, and 300 000 cells were used for staining. Cells were fixed in 80% ethanol and stored at −20 ∘ C overnight. Fixed cells were washed in PBS and incubated for 30 min at room temperature in 50 μg/ml RNaseA and 50 μg/ml propidium iodiode (PI) solutions, and then placed on ice until analysis. An LSRII flow cytometer (BD Biosciences, San José, CA, USA) supplied with FACSDiva software was used for acquisition. A Sapphire 488 nm, 20 mW laser (Coherent, Santa Clara, CA) was used for excitation of PI and fluorescence was collected using a 610/20 nm band-pass filter. Using the PI pulse-width versus PI pulse-area signals, a life gate was set during acquisition allowing the collection of 40 000 single cell events. A data file contained all events including debris and clumps. The voltage of the PI detector was adjusted to set the mean of the G0/G1 population at channel 50 000. The data were analysed using WinList 7.1 and Modfit 3.3. software packages (Verity Software House, Inc, Topsham, ME, USA) and reports were generated automatically. The S-phase was calculated using the polynomial model, which gave the best fit of the data as calculated by a reduced chi-squared test (<3%). The coefficient of variation (CV) of the G0/1 population never exceeded 4%, demonstrating the high quality of the generated DNA histograms.
Transwell invasion assay
TGFβ-signalling blockade increases tumour growth and metastasis 747 upper chambers of the wells in 0.2% FCS, while the FCS concentration in the lower chamber was 10%.
Twenty-four hours after adding appropriate concentrations of TGFβ1 and SD-208 to both chambers, cells on the filter were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet. Cells in at least three random microscopic fields (20×) per membrane were counted.
Animals
Female athymic nude mice (Balb/c nu/nu) were purchased from Charles River (L'Arbresle, France) and housed in individual ventilated cages under sterile conditions; sterile food and water were provided ad libitum. Animal experiments were approved by the local committee for animal health, ethics, and research of Leiden University and carried out in accordance with European Communities Council Directive 86/609/EEC. After the experimental periods, mice were anaesthetised and sacrificed by cervical dislocation. Tumours were dissected and processed for further histomorphometrical analysis as described earlier [21] .
Animal models
Tumours cells were harvested at 70-80% confluence and immediately stored on ice before inoculation in vivo.
In the intracardiac inoculation model, mice were anaesthetised with an induction dose of 3% isoflurane and maintained under anaesthesia at a dose of 1% isoflurane. In the intra-osseous inoculation model and the surgical resection of the orthotopic tumour, mice were anaesthetised with an induction dose of 3% isoflurane and maintained under anaesthesia at a dose of 2-3% isoflurane.
In the intracardiac inoculation model, a single-cell suspension of 10 5 cells/100 μl of PBS was injected into the left cardiac ventricle in isoflurane-anaesthetised 6-week-old mice using a 30-gauge needle (30G 1/2, BDMicro-Fine; Becton Dickinson, Etten-Leur, The Netherlands) [22] . In the intra-osseous inoculation model, a single-cell suspension of 10 5 cells/100 μl of PBS was injected into the right tibia of 7-week-old mice [23] . Tibiae were sutured with stainless steel autoclips (Leica Biosystems, Nussloch, Germany), which were gently removed 1 week later.
In the orthotopic model, the fourth inguinal mammary pad of non-anaesthetised 7-week-old mice was gently grasped and lifted using a forceps. A 25-gauge needle (25G 5/8, BDMicro-Fine; Becton Dickinson), bevel side up, was inserted just under the nipple, taking special care not to push the needle into the abdominal cavity. Upon release of the gland, a single-cell suspension of 10 5 cells/10 μl of PBS was slowly injected into the mammary fat pad.
A mastectomy was conducted on isofluraneanaesthetised mice in which the orthotopic tumours were separated from adherent tissues using forceps and excised and stored for further analysis. When during a mastectomy positive lymph nodes were detected using bioluminescent imaging (BLI), these were also surgically resected. When no detectable residual tumour was found, the surgical incision was closed with stainless steel autoclips.
In the group with large tumours (10 8 photons/s), three mice were excluded from the group as significant weight loss was observed before they reached the criteria of a large tumour (10 8 photons/s).
TβRI inhibitor treatment
Mice were treated with vehicle (1% methylcellulose) or SD-208 (60 mg/kg once daily) by oral gavage [15] .
No adverse effects of SD-208 on mouse health were detected during the study (Supplementary Figure 1) .
Whole-body bioluminescent imaging (BLI)
Tumour growth was monitored by whole-body BLI using an intensified-charge-coupled device (I-CCD) video camera of the in vivo Imaging System (IVIS100; Xenogen/Perkin Elmer, Alameda, CA, USA) as described previously [22] . In the SD-208 experimental treatment experiment, the newer IVIS Lumina II (Xenogen/Perkin Elmer) was used for BLI measurements. Mice were anaesthetised using isoflurane and injected i. 
Immunofluorescence
Immunofluorescent staining was performed as described previously [24] . In brief, fixed paraffin-embedded tissues were sectioned at 5 μm. 
Statistical analysis
Statistical analysis was performed with GraphPad Prism 6.0 software (GraphPad Software Inc, San Diego, CA, USA) with the use of an unpaired Student's t-test (for comparison between two groups), a one-way ANOVA with Tukey's multiple comparison test or a two-way ANOVA with Bonferroni's multiple comparison test as stated in the figure legends. All in vitro experiments were performed at least three times. Unless stated otherwise, data are represented as mean ± SEM. p values less than 0.05 were regarded as being statistically significant (*p < 0.05, **p < 0.01, and ***p < 0.001).
Results
Orthotopic, intracardiac, and intra-osseous models
In order to develop novel preclinical models for ILC, KEP cells were tested in three different in vivo models, namely orthotopic, intracardiac, and intra-osseous inoculation models. Orthotopic inoculation of athymic nude mice with either KEP11/Luc or KEP23/Luc cells resulted in 100% tumour take rate ( Figures 1A and 1B) . Based on BLI measurements, the orthotopic growth of KEP11/Luc was significantly higher than that of KEP23/Luc ( Figures 1A and 1B) . KEP tumour cells were small in size, had pleiomorphic nuclei, coarsely clumped chromatin, and spare cytoplasm ( Figure 1C ). In addition, KEP cells were CK8-positive, occasionally Figure 2 ). After surgical removal of orthotopically implanted tumours, mice appeared tumour-free, as assessed with BLI imaging. Within 3 weeks, however, the formation of distant bone metastases was observed in the axial and appendicular skeleton, including vertebral and tibial metastases ( Figure 1C ). It is important to note that no overt lung metastases were detected 5 weeks after resection of the orthotopic tumour using BLI. Histological analysis confirmed minimal lung involvement, showing that only 10% (1/10) presented with a micrometastasis ( Figure 1C) .
Inoculation of KEP11/Luc and KEP23/Luc cells into the left cardiac ventricle led to the rapid development of bone metastases with a comparable distribution pattern and 100% distant tumour take rate ( Figures 1D  and 1E and Supplementary Figure 3) . To further test the ability of KEP cells to grow in the bone marrow microenvironment, tumour cells were injected in the tibiae. Again, the tumour take rate was 100% ( Figure 1F ), and the bone phenotype was found to be mixed, with destruction of both cortical bone and ectopic bone formation as shown on 3D μCT images and histological sections ( Figure 1G) .
Next, we further refined the orthotopic model by resecting orthotopic tumours of three different sizes (N = 10) based on BLI signal intensity: namely, small-sized tumour [10 6 photons/(s ⋅ cm 2 ⋅ sr)]; medium-sized tumour [10 7 photons/(s ⋅ cm 2 ⋅ sr)]; and large-sized tumour [10 8 photons/(s ⋅ cm 2 ⋅ sr)]. At the time (corresponding to 12 ± 0 days after orthotopic injection) that small tumours were resected, no distant metastases were present. In the following 2 weeks, only 10% (1/10) of the mice developed a distant metastasis ( Figures 2C and 2D) . Moreover, no additional metastases developed in the following 3 weeks (data not shown). When medium orthotopic tumours were resected (corresponding to 25 ± 2 days after orthotopic injection), 20% (2/10) of the mice had already presented with at least one distant metastasis. In the following 2 weeks, 60% (6/10) of the mice developed distant metastases ( Figures 2C and 2D) . When larger-sized tumours were resected (corresponding to 39 ± 2 days after orthotopic injection), 43% (3/7) of the mice had already developed detectable distant metastases at the time of surgery. In the 2 weeks after surgery, 86% (6/7) of the mice had developed at least one distant metastasis ( Figures 2C  and 2D ).
TGFβ stimulates Smad-dependent signalling in KEP cells
To test the ability of the tumour cells to respond to TGFβ1 administration, we transiently transfected the KEP11/firefly-luciferase clone with a Smad-dependent TGFβ-reporter construct CAGA linked to Renilla luciferase (RL). Stimulation with 5 ng/ml TGFβ1 for 24 h resulted in a strong increase (29.5×) in the activity of the CAGA reporter. The TβRI kinase inhibitor SD-208 partially blocked TGFβ-induced signalling at a concentration of 0.1 μM (66% inhibition, p < 0.05) and almost completely blocked TGFβ-induced signalling at a concentration of 1 μM (84% inhibition, p < 0.001) ( Figure 3A ).
TGFβ treatment affects cellular morphology and migration
Our in vitro data show that treatment with both SD-208 and TGFβ1 exerts morphological changes in tumour cells. While SD-208-treated cells displayed a cuboidal shape and grew in clusters ( Figure 3B, IV) , cells treated Figure 3B , V and VI). Furthermore, we found that TGFβ1 induced a dose-dependent increase in the migration of the cancer cells. Again, the pro-invasive TGFβ1 response was attenuated upon addition of SD-208 ( Figure 3C ).
TGFβ decreases cellular viability via induction of apoptosis and G1/G0 cell cycle arrest
After 48 h, TGFβ1 (1 and 10 ng/ml) decreased the number of viable cells. This decrease was completely reversed upon co-incubation with SD-208 ( Figure 3D ). Next, we studied whether induction of apoptosis or inhibition of proliferation accounts for the observation that TGFβ treatment resulted in reduced numbers of KEP cells.
As assessed by a caspase-3/7 activity assay, addition of 1 and 10 ng/ml TGFβ1 for 24 h significantly induced apoptosis by 68.0% and 68.2%, respectively ( Figure 3E ). No significant induction of apoptosis was observed when cells were co-incubated with SD-208.
Next, it was tested whether TGFβ1 treatment also reduced the number of viable cells by inhibiting proliferation via G0/1 arrest. Treatment of the cells with 10 ng/ml TGFβ for 24 and 48 h showed a significant increase in the G0/G1-phase of the cell cycle. Co-incubation with SD-208 was also able to completely block the TGFβ1-induced increase in the G0/1-phase ( Figures 4A and 4B) . Furthermore, treatment with SD-208 alone for 24 h decreased the percentage of cells in the G0/G1-phase significantly (p < 0.05), along with a significant increase in the S-phase (Supplementary Figure 4) .
To test the role of TGFβ signalling in our MRD model of lobular carcinoma of the breast, we treated mice daily with 60 mg/kg SD-208 in a continuous or adjuvant setting ( Figure 5A ). Based on the data described in Figure 2 and the practical need to have a fixed time point, we chose 4 weeks as the time point for surgical resection after orthotopic inoculation of KEP11/Luc cells. Continuous treatment with SD-208 for 4 weeks of orthotopically implanted tumour cells resulted in significantly increased tumour growth in the mammary glands ( Figure 5B ). In addition, continuous SD-208 treatment resulted in a significant increase of the number of distant metastases 4 weeks after surgical removal and a clear trend for increased metastatic tumour burden ( Figure 5C ). Adjuvant SD-208 treatment, which was started after surgical resection of the tumour, also resulted in a significant increase in the number of distant metastases 5 weeks after surgical removal ( Figure 5C ). Immunolocalisation of phosphorylated Smad2 as a marker for Smad-dependent TGFβ signalling confirmed that both tumour cells and 
Discussion
We have developed a novel mouse model of MRD for invasive lobular breast cancer that recapitulates the key events of the metastatic cascade. Using whole-body BLI, we performed cancer cell tracking and therapy response in real time. We mimicked the clinical setting by surgical resection of orthotopic tumours to extend the life span of the animals, thus allowing disseminated cancer cells to develop into overt metastases. As a result, mice eventually succumbed to widespread metastatic bone disease without overt lung metastases that hamper the life span of the animals. Our model provides a valuable tool to study dissemination to bone of ILC and offers several advantages over most of the currently available metastasis models.
Metastasis formation in our model is not induced by systemic (intravenous, intracardiac) injection of cancer cells, but occurs spontaneously from the orthotopic site. Thus, metastatic dissemination in this model more closely reflects the initial key biological events of the metastatic cascade. While in most other orthotopic breast cancer models bone metastases are not observed, our preclinical model includes mainly skeletal metastases with minimal lung involvement. This seems to be a major advantage over the murine 4 T1 model [7] [8] [9] . Furthermore, BLI allows sensitive non-invasive monitoring of orthotopic tumour growth and metastasis in real time. This model seems to be ideally suited for testing novel therapeutic agents and treatment protocols aiming at preventing or treating metastatic disease. As shown by our intervention experiments, this can be performed in either an adjuvant or a neoadjuvant setting, thus allowing a careful and independent evaluation of therapeutic agents targeting the primary tumour, dissemination of tumour cells, and/or metastatic bone disease. In the model described here, BLI comes at the expense of an immune-proficient microenvironment because luciferase-expressing tumour cells might provoke a specific immune response to luciferase [25] . Without the use of in vivo non-invasive imaging markers, Doornebal et al elegantly showed that serial transplantation of fragments of KEP tumours also resulted in the formation of distant metastases from orthotopic sites in a syngeneic model, although the involvement of metastasis to bone was not explicitly mentioned [26] .
It has been well documented that TGFβ has a dual role in cancer development. While the anti-tumourigenic effects are generally most prominent during the initial steps of carcinogenesis, pro-tumourigenic effects may prevail at later stages [11, 27] . While the net effect of TGFβ in several mouse models of IDC is clearly pro-tumourigenic, the anti-tumour effects of TGFβ predominate in our ILC mouse model through stimulation of apoptosis and induction of a G0/1 arrest.
Although not dominating the overall effect, pro-tumourigenic effects on migration may also occur in vivo. The number of metastases formed after resection of the orthotopic tumour was comparable in mice treated continuously or in the adjuvant setting. However, the orthotopic tumours that were resected were bigger in the mice that were treated continuously versus those in an adjuvant setting (no SD-208 before surgical resection). Despite SD-208-induced stimulation of orthotopic tumour growth, SD-208 may therefore still display its (less prominent) anti-invasive properties. While SD-208 increased tumour growth in our model, many studies have shown that TGFβ blockade decreased tumour progression and metastasis in mouse models of IDC [17, [28] [29] [30] . Using 4 T1 and MDA-MB-231 IDC cells, Liu et al recently reported that TGFβ blockade not only inhibited orthotopic tumour growth, but also improved the penetration of chemotherapeutic drugs by normalization of the intratumoural vascularization and decreasing collagen I production [29] . Although pharmacological blockade of the TGFβ pathway may not diminish tumour growth in our ILC model, it is tempting to speculate that the observed increase in proliferation may even be exploited therapeutically when used in combination with chemotherapeutic agents.
Gene expression profiling studies have suggested that deregulated TGFβ signalling is more important in ILC than in IDC [31, 32] . However, interpretation of these results is hampered by the fact that the affected gene expression patterns are not consistent in comparable studies using different patient populations and cohorts [31] [32] [33] [34] [35] . Based on the high sensitivity to the anti-tumourigenic effects of TGFβ in our ILC model, or rather the stimulatory effect on tumour growth upon TGFβ signalling blockage, it would be highly interesting to study functionally whether ILC patients are more sensitive to the anti-tumourigenic effects of TGFβ than IDC patients. The outcome of these studies may be of help in deciding which group of patients should be included in intervention studies with TGFβ blockers.
In conclusion, we developed a novel preclinical orthotopic model of ILC that will lead to spontaneous bone (micro)metastasis with no (significant) lung involvement. In addition, pharmacological treatment with the small molecule SD-208, a TβRI kinase inhibitor, stimulated tumour growth at primary and metastatic sites, indicating that anti-tumour effects prevail in this model.
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